Innovating Works

BLUEPHARMA

OncoNanoR: Engineering the immunosuppressive microenvironment in mesothelioma with targeted LipidNanoParticles... BLUEPHARMA INDUSTRIA FARMACEUTICASA participó en un HORIZON EUROPE: HORIZON-WIDERA-2022-TALENTS-02 Malignant pleural mesothelioma (MPM) is a highly aggressive disease, where chemotherapy remains the standard of care, enabling an overall su...
2022-09-19 - 2025-06-30 | Financiado
FOLSMART: Folate Target Nanodevices To Activated Macrophages For Rheumatoid Arthritis BLUEPHARMA INDUSTRIA FARMACEUTICASA participó en un H2020: H2020-NMP-2014-2015 FOLSMART will bring to phase I clinical trials novel folate-based nanodevices (FBN) for the treatment of rheumatoid arthritis (RA). These na...
2015-11-25 - 2020-12-31 | Financiado
GLORIA: Comparing the effectiveness and safety of additional low dose glucocorticoid in treatment strategies... BLUEPHARMA INDUSTRIA FARMACEUTICASA participó en un H2020: H2020-PHC-2014-2015 GLORIA aims to prove that the addition of chronic low dose glucocorticoids (GC) to current antirheumatic therapy is highly cost-effective an...
2015-04-08 - 2021-08-31 | Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.